Staff Profile: Valery M. Gordon

Valery M. Gordon, Ph.D., M.P.H.

Senior Advisor for Human Subjects Protection

Division of Clinical Innovation

National Center for Advancing Translational Sciences

National Institutes of Health

Email Valery M. Gordon


Valery Gordon is the senior advisor for human subjects protection in NCATS’ Division of Clinical Innovation (DCI), where she assists the DCI director and the Trial Innovation Network director with issues related to human research protections. Prior to joining NCATS in November 2017, she led the Clinical Research Policy Program in the NIH Office of Science Policy. Gordon also served as the director for the Human Subjects Protection Program in the NIH Office of Extramural Research, the NIH extramural research integrity liaison officer, and the director of the Office of Extramural Policy in the National Institute of Biomedical Imaging and Bioengineering’s Office of Research Administration.

In addition to working in the policy arena, Gordon served as a certified biosafety officer in the Office of Research Services, where she oversaw the NIH pathogen registry. She also served as a responsible official for select agent use in the NIH Intramural Research Program,  executive secretary of the NIH Institutional Biosafety Committee, and a member of the NIH Clinical Center Ethics Committee.

Gordon received her Ph.D. in pharmacology from the University of Virginia and her M.P.H. in bioethics and health policy from the Johns Hopkins School of Hygiene and Public Health.

Research Topics

Gordon’s research interests focus on microbial pathogenesis — specifically, mechanisms of action of bacterial toxins — and on clinical research ethics.

Selected Publications

  1. Final NIH Policy on the Use of a Single Institutional Review Board for Multisite Research.
  2. Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials.
  3. Clostridium septicum alpha-toxin is proteolytically activated by furin.
  4. An enzymatic mutant of Shiga-like toxin II variant is a vaccine candidate for edema disease of swine.
  5. Adenylate cyclase toxins from Bacillus anthracis and Bordetella pertussis. Different processes for interaction with and entry into target cells.